Citadel Advisors’s Bone Biologics BBLG Stock Holding History

Citadel Advisors’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,844	Closed	-$15.7K	–	12978
2025 Q4	$15.7K	Buy	+10,844	New	+$21.6K	﹤0.01%	12393
2023 Q4	–	Sell	-236	Closed	-$8.05K	–	14260
2023 Q3	$8.05K	Buy	+236	New	+$11.7K	﹤0.01%	13223
2022 Q2	–	Sell	-7	Closed	-$30K	–	12864
2022 Q1	$30K	Buy	+7	New	+$25.4K	﹤0.01%	13099

Other funds holding BBLG

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's BBLG Position: Q1 2026 in Review

Citadel Advisors sold out of Bone Biologics (BBLG) in Q1 2026, closing a stake of 10,844 shares — an estimated $15.7K sold.

Citadel Advisors first reported a position in BBLG in Q1 2022 and held it in 3 quarters. The position peaked at $30K in Q1 2022. 3 funds tracked by Wall St. Rank hold BBLG as of Q1 2026.

Citadel Advisors reported no remaining Bone Biologics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 10,844 Bone Biologics shares in Q1 2026, an estimated $15.7K.
Citadel Advisors first reported a position in Bone Biologics in Q1 2022 and held it in 3 quarters.
Citadel Advisors's Bone Biologics position peaked at $30K in Q1 2022.
3 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.